ORAL-CONTRACEPTIVES AND ENDOMETRIAL AND OVARIAN CARCINOMAS

Combined oral contraceptives reduce the risk of endometrial and ovaria n cancer by about 50%. The risk of both carcinomas decreases with an i ncreasing duration of oral contraceptive use. The reduced risk lasts f or 10-15 years after cessation. A significantly lower risk of developi ng oral contraceptives reduce the risk of endometrial and ovarian canc er by about an endometrial carcinoma can be observed for contraceptive s with a high progestin and a low estrogen concentration. Due to the p rotective effect, the use of oral contraceptives is a useful means for primary prevention (chemoprevention) in women at high risk of endomet rial and ovarian cancers.